Long-term maintenance of patient-specific characteristics in tumoroids from six cancer indications in a common base culture media system
Colin D Paul,Chris Yankaskas,Pradip Shahi Thakuri,Brittany Balhouse,Shyanne Salen,Amber Bullock,Sylvia Beam,Anthony Chatman,Sybelle Djikeng,Xiaoyu Jenny Yang,Garrett Wong,Isha Dey,Spencer Holmes,Abigail Dockey,Lindsay Bailey-Steinitz,Lina Zheng,Weizhong Li,Vivek Chandra,Jakhan Nguyen,Jason Sharp,Erik Willems,Mark Kennedy,Matt Dallas,David Kuninger
DOI: https://doi.org/10.1101/2024.06.10.598331
2024-06-12
Abstract:Tumoroids, also known as cancer organoids, are patient-derived cancer cells grown as 3D, self-organized multicellular structures that maintain key characteristics (e.g., genotype, gene expression levels) of the tumor from which they originated. These models have emerged as valuable tools for studying tumor biology, cytotoxicity, and response of patient-derived cells to cancer therapies. However, the establishment and maintenance of tumoroids has historically been challenging, labor intensive, and highly variable from lab to lab, hindering their widespread use. Here, we characterize the establishment and/or expansion of colorectal, lung, head and neck, breast, pancreas, and endometrial tumoroids using the standardized, serum-free Gibco™ OncoPro™ Tumoroid Culture Medium. Newly derived tumoroid lines (n=20) were analyzed by targeted genomic profiling and RNA sequencing and were representative of tumor tissue samples. Tumoroid lines were stable for over 250 days in culture and freeze-thaw competent. Previously established tumoroid lines were also transitioned to OncoPro medium and exhibited, on average, similar growth rates and conserved donor-specific characteristics when compared to original media systems. Additionally, OncoPro medium was compatible with both embedded culture in extracellular matrix and growth in a suspension format for facile culture and scale up. An example application of these models for assessing the cytotoxicity of a natural killer cell line and primary natural killer cells over time and at various doses demonstrated the compatibility of these models with assays used in compound and cell therapy development. We anticipate that the standardization and versatility of this approach will have important benefits for basic cancer research, drug discovery, and personalized medicine and help make tumoroid models more accessible to the cancer research community.
Cancer Biology